Furthermore, three clinical trials of CD19-targeting CAR-NKT cells (NCT03774654, NCT05487651, NCT04814004) for the treatment of B cell lymphoma are ongoing (Table 2), but no data have been published yet. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.